About Us
The Otsuka Patient Assistance Foundation, Inc (OPAF) is a nonprofit 501c(3) organization that provides free treatment to eligible uninsured and underinsured patients that have been prescribed:
ABILIFY MAINTENA® (aripiprazole) extended-release injectable suspension
ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension
NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) capsules
JYNARQUE® (tolvaptan) tablets
REXULTI® (brexpiprazole) tablets
VOYXACT® (sibeprenlimab-szsi) injection
See GLOBAL FULL PRESCRIBING INFORMATION for NUEDEXTA and VOYXACT.
See U.S. FULL PRESCRIBING INFORMATION, including BOXED WARNING for ABILIFY MAINTENA, ABILIFY ASIMTUFII, JYNARQUE, and REXULTI.
See MEDICATION GUIDES for ABILIFY MAINTENA, ABILIFY ASIMTUFII, JYNARQUE, and REXULTI.
The OPAF Origin Story
Since the first enrolled patient in March 2017, OPAF has helped over 127,000 patients with 475,000 prescriptions shipped.
What started as an independent entity funded by donations from Otsuka America Pharmaceuticals, Inc., has become the OPAF of today: an independent 501c3 organization committed to the mental, emotional, and physical well-being of patients and their caregivers throughout their health journey.
The Independent Volunteer OPAF Board of Directors & Leadership Team
Christina Van Derveer
Corporate Officer